Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04639245
Title Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Fred Hutchinson Cancer Research Center

transitional cell carcinoma

lung non-small cell carcinoma

triple-receptor negative breast cancer


MAGE-A1-specific TCR cells + unspecified PD-1 antibody

Cyclophosphamide + Fludarabine

Atezolizumab + MAGE-A1-specific TCR cells

MAGE-A1-specific TCR cells

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST